{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:06:05Z","timestamp":1761102365634,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T00:00:00Z","timestamp":1554681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["099246\/Z\/12\/Z","099246\/Z\/12\/Z","099246\/Z\/12\/Z","099246\/Z\/12\/Z","099246\/Z\/12\/Z","099246\/Z\/12\/Z"],"award-info":[{"award-number":["099246\/Z\/12\/Z","099246\/Z\/12\/Z","099246\/Z\/12\/Z","099246\/Z\/12\/Z","099246\/Z\/12\/Z","099246\/Z\/12\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/J000612\/1"],"award-info":[{"award-number":["MR\/J000612\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The surfaceome is critical because surface proteins provide a gateway for internal signals and transfer of molecules into cells, and surfaceome differences can influence therapy response. We have used a surfaceome analysis method, based on comparing RNA-seq data between normal and abnormal cells (<jats:underline>S<\/jats:underline>urfaceome <jats:underline>D<\/jats:underline>ata<jats:underline>B<\/jats:underline>ase <jats:underline>M<\/jats:underline>ining or <jats:underline>S<\/jats:underline>urfaceome <jats:underline>DBM<\/jats:underline>), to identify sets of upregulated cell surface protein mRNAs in an LMO2-mediated T-ALL mouse model and corroborated by protein detection using antibodies. In this model the leukemia initiating cells (LICs) comprise pre-leukaemic, differentiation inhibited thymocytes allowing us to provide a profile of the LIC surfaceome in which GPR56, CD53 and CD59a are co-expressed with CD25. Implementation of cell surface interaction assays demonstrates fluid interaction of surface proteins and CD25 is only internalized when co-localized with other proteins. The Surfaceome DBM approach to analyse cancer cell surfaceomes is a way to find targetable surface biomarkers for clinical conditions where RNA-seq data from normal and abnormal cell are available.<\/jats:p>","DOI":"10.1038\/s41598-019-42214-w","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T10:04:10Z","timestamp":1554717850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model"],"prefix":"10.1038","volume":"9","author":[{"given":"Helio","family":"Pais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Ruggero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama","family":"Al-Assar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2643-3897","authenticated-orcid":false,"given":"Nicolas","family":"Bery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravneet","family":"Bhuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Weston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela R.","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1623-0148","authenticated-orcid":false,"given":"Cristina","family":"Mecucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4982-2609","authenticated-orcid":false,"given":"Terence H.","family":"Rabbitts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"42214_CR1","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1073\/pnas.1521251113","volume":"113","author":"J Town","year":"2016","unstructured":"Town, J. et al. Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target. Proc Natl Acad Sci USA 113, 3603\u20133608, https:\/\/doi.org\/10.1073\/pnas.1521251113 (2016).","journal-title":"Proc Natl Acad Sci USA"},{"key":"42214_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature19949","volume":"537","author":"R Aebersold","year":"2016","unstructured":"Aebersold, R. & Mann, M. Mass-spectrometric exploration of proteome structure and function. Nature 537, 347\u2013355, https:\/\/doi.org\/10.1038\/nature19949 (2016).","journal-title":"Nature"},{"key":"42214_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.molcel.2013.01.029","volume":"49","author":"M Mann","year":"2013","unstructured":"Mann, M., Kulak, N. A., Nagaraj, N. & Cox, J. The coming age of complete, accurate, and ubiquitous proteomes. Mol Cell 49, 583\u2013590, https:\/\/doi.org\/10.1016\/j.molcel.2013.01.029 (2013).","journal-title":"Mol Cell"},{"key":"42214_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel, C. & Marcotte, E. M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 13, 227\u2013232, https:\/\/doi.org\/10.1038\/nrg3185 (2012).","journal-title":"Nat Rev Genet"},{"key":"42214_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.molcel.2017.01.023","volume":"65","author":"C Ziegenhain","year":"2017","unstructured":"Ziegenhain, C. et al. Comparative Analysis of Single-Cell RNA Sequencing Methods. Mol Cell 65, 631\u2013643 e634, https:\/\/doi.org\/10.1016\/j.molcel.2017.01.023 (2017).","journal-title":"Mol Cell"},{"key":"42214_CR6","first-page":"853","volume":"11","author":"RC Larson","year":"1995","unstructured":"Larson, R. C., Osada, H., Larson, T. A., Lavenir, I. & Rabbitts, T. H. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene 11, 853\u2013862 (1995).","journal-title":"Oncogene"},{"key":"42214_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1126\/science.1182378","volume":"327","author":"MP McCormack","year":"2010","unstructured":"McCormack, M. P. et al. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science 327, 879\u2013883, https:\/\/doi.org\/10.1126\/science.1182378 (2010).","journal-title":"Science"},{"key":"42214_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/j.1460-2075.1996.tb00439.x","volume":"15","author":"RC Larson","year":"1996","unstructured":"Larson, R. C. et al. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J 15, 1021\u20131027 (1996).","journal-title":"EMBO J"},{"key":"42214_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0037-1963(03)00195-1","volume":"40","author":"AA Ferrando","year":"2003","unstructured":"Ferrando, A. A. & Look, A. T. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematology 40, 274\u2013280 (2003).","journal-title":"Semin Hematology"},{"key":"42214_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","volume":"1","author":"AA Ferrando","year":"2002","unstructured":"Ferrando, A. A. et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75\u201387 (2002).","journal-title":"Cancer Cell"},{"key":"42214_CR11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 49, 1211\u20131218, https:\/\/doi.org\/10.1038\/ng.3909 (2017).","journal-title":"Nat Genet"},{"key":"42214_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/77819","volume":"1","author":"S Herblot","year":"2000","unstructured":"Herblot, S., Steff, A. M., Hugo, P., Aplan, P. D. & Hoang, T. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol 1, 138\u2013144, https:\/\/doi.org\/10.1038\/77819 (2000).","journal-title":"Nat Immunol"},{"key":"42214_CR13","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.1128\/MCB.23.24.9003-9013.2003","volume":"23","author":"MP McCormack","year":"2003","unstructured":"McCormack, M. P., Forster, A., Drynan, L., Pannell, R. & Rabbitts, T. H. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mol Cell Biol 23, 9003\u20139013 (2003).","journal-title":"Mol Cell Biol"},{"key":"42214_CR14","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.V72.6.1891.1891","volume":"72","author":"WM Crist","year":"1988","unstructured":"Crist, W. M. et al. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study. Blood 72, 1891\u20131897 (1988).","journal-title":"Blood"},{"key":"42214_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng, S. W. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433\u2013437, https:\/\/doi.org\/10.1038\/nature20598 (2016).","journal-title":"Nature"},{"key":"42214_CR16","first-page":"2848","volume":"62","author":"M Peipp","year":"2002","unstructured":"Peipp, M. et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res 62, 2848\u20132855 (2002).","journal-title":"Cancer Res"},{"key":"42214_CR17","first-page":"108","volume":"44","author":"DM Lee","year":"1996","unstructured":"Lee, D. M. et al. The mouse CD7 gene: identification of a new element common to the human CD7 and mouse Thy-1 promoters. Immunogenetics 44, 108\u2013114 (1996).","journal-title":"Immunogenetics"},{"key":"42214_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/intimm\/13.2.157","volume":"13","author":"CS Heinly","year":"2001","unstructured":"Heinly, C. S. et al. Comparison of thymocyte development and cytokine production in CD7-deficient, CD28-deficient and CD7\/CD28 double-deficient mice. Int Immunol 13, 157\u2013166 (2001).","journal-title":"Int Immunol"},{"key":"42214_CR19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.stem.2017.02.010","volume":"20","author":"G Richard-Carpentier","year":"2017","unstructured":"Richard-Carpentier, G. & Sauvageau, G. Bringing a Leukemic Stem Cell Gene Signature into Clinics: Are We There Yet? Cell Stem Cell 20, 300\u2013301, https:\/\/doi.org\/10.1016\/j.stem.2017.02.010 (2017).","journal-title":"Cell Stem Cell"},{"key":"42214_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep02854","volume":"3","author":"S Cabantous","year":"2013","unstructured":"Cabantous, S. et al. A new protein-protein interaction sensor based on tripartite split-GFP association. Sci Rep 3, 2854, https:\/\/doi.org\/10.1038\/srep02854 (2013).","journal-title":"Sci Rep"},{"key":"42214_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.molcel.2016.12.004","volume":"65","author":"Z Yao","year":"2017","unstructured":"Yao, Z. et al. A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome. Mol Cell 65, 347\u2013360, https:\/\/doi.org\/10.1016\/j.molcel.2016.12.004 (2017).","journal-title":"Mol Cell"},{"key":"42214_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nmeth.2895","volume":"11","author":"J Petschnigg","year":"2014","unstructured":"Petschnigg, J. et al. The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells. Nat Methods 11, 585\u2013592, https:\/\/doi.org\/10.1038\/nmeth.2895 (2014).","journal-title":"Nat Methods"},{"key":"42214_CR23","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","volume":"129","author":"DI Marks","year":"2017","unstructured":"Marks, D. I. & Rowntree, C. Management of adults with T-cell lymphoblastic leukemia. Blood 129, 1134\u20131142, https:\/\/doi.org\/10.1182\/blood-2016-07-692608 (2017).","journal-title":"Blood"},{"key":"42214_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/MOH.0000000000000058","volume":"21","author":"CS Tremblay","year":"2014","unstructured":"Tremblay, C. S. & Curtis, D. J. The clonal evolution of leukemic stem cells in T-cell acute lymphoblastic leukemia. Curr Opin Hematol 21, 320\u2013325, https:\/\/doi.org\/10.1097\/MOH.0000000000000058 (2014).","journal-title":"Curr Opin Hematol"},{"key":"42214_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/gcc.22416","volume":"56","author":"K Karrman","year":"2017","unstructured":"Karrman, K. & Johansson, B. Pediatric T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer 56, 89\u2013116, https:\/\/doi.org\/10.1002\/gcc.22416 (2017).","journal-title":"Genes Chromosomes Cancer"},{"key":"42214_CR26","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/367645a0","volume":"367","author":"T Lapidot","year":"1994","unstructured":"Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645\u2013648, https:\/\/doi.org\/10.1038\/367645a0 (1994).","journal-title":"Nature"},{"key":"42214_CR27","doi-asserted-by":"publisher","first-page":"e39725","DOI":"10.1371\/journal.pone.0039725","volume":"7","author":"W Ma","year":"2012","unstructured":"Ma, W. et al. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One 7, e39725, https:\/\/doi.org\/10.1371\/journal.pone.0039725 (2012).","journal-title":"PLoS One"},{"key":"42214_CR28","first-page":"3675","volume":"9","author":"RC Larson","year":"1994","unstructured":"Larson, R. C. et al. T cell tumours of disparate phenotype in mice transgenic for Rbtn-2. Oncogene 9, 3675\u20133681 (1994).","journal-title":"Oncogene"},{"key":"42214_CR29","doi-asserted-by":"publisher","unstructured":"Ruggero, K. et al. LMO2 and IL2RG synergize in thymocytes to mimic the evolution of SCID-X1 gene therapy-associated T-cell leukaemia. Leukemia, https:\/\/doi.org\/10.1038\/leu.2016.116 (2016).","DOI":"10.1038\/leu.2016.116"},{"key":"42214_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nmeth.1226","volume":"5","author":"A Mortazavi","year":"2008","unstructured":"Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5, 621\u2013628, https:\/\/doi.org\/10.1038\/nmeth.1226 (2008).","journal-title":"Nat Methods"},{"key":"42214_CR31","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1006\/geno.1998.5644","volume":"55","author":"M Liu","year":"1999","unstructured":"Liu, M. et al. GPR56, a novel secretin-like human G-protein-coupled receptor gene. Genomics 55, 296\u2013305, https:\/\/doi.org\/10.1006\/geno.1998.5644 (1999).","journal-title":"Genomics"},{"key":"42214_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1096\/fasebj.11.6.9194523","volume":"11","author":"HT Maecker","year":"1997","unstructured":"Maecker, H. T., Todd, S. C. & Levy, S. The tetraspanin superfamily: molecular facilitators. FASEB J 11, 428\u2013442 (1997).","journal-title":"FASEB J"},{"key":"42214_CR33","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","volume":"95","author":"J Golay","year":"2000","unstructured":"Golay, J. et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95, 3900\u20133908 (2000).","journal-title":"Blood"},{"key":"42214_CR34","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","volume":"98","author":"J Golay","year":"2001","unstructured":"Golay, J. et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98, 3383\u20133389 (2001).","journal-title":"Blood"},{"key":"42214_CR35","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood.V98.9.2771","volume":"98","author":"B Bellosillo","year":"2001","unstructured":"Bellosillo, B. et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98, 2771\u20132777 (2001).","journal-title":"Blood"},{"key":"42214_CR36","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-10-3016","volume":"71","author":"W Hu","year":"2011","unstructured":"Hu, W. et al. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res 71, 2298\u20132307, https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3016 (2011).","journal-title":"Cancer Res"},{"key":"42214_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","volume":"67","author":"C Spiess","year":"2015","unstructured":"Spiess, C., Zhai, Q. & Carter, P. J. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 67, 95\u2013106, https:\/\/doi.org\/10.1016\/j.molimm.2015.01.003 (2015).","journal-title":"Mol Immunol"},{"key":"42214_CR38","doi-asserted-by":"publisher","first-page":"22579","DOI":"10.18632\/oncotarget.8022","volume":"7","author":"CC Roskopf","year":"2016","unstructured":"Roskopf, C. C. et al. Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells. Oncotarget 7, 22579\u201322589, https:\/\/doi.org\/10.18632\/oncotarget.8022 (2016).","journal-title":"Oncotarget"},{"key":"42214_CR39","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1365-2141.2010.08300.x","volume":"150","author":"M Kugler","year":"2010","unstructured":"Kugler, M. et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 150, 574\u2013586, https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08300.x (2010).","journal-title":"Br J Haematol"},{"key":"42214_CR40","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.4161\/cc.7.11.6061","volume":"7","author":"T Tanaka","year":"2008","unstructured":"Tanaka, T. & Rabbitts, T. H. Interfering with protein-protein interactions: potential for cancer therapy. Cell Cycle 7, 1569\u20131574, https:\/\/doi.org\/10.4161\/cc.7.11.6061 (2008).","journal-title":"Cell Cycle"},{"key":"42214_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature19764","volume":"538","author":"MP Stewart","year":"2016","unstructured":"Stewart, M. P. et al. In vitro and ex vivo strategies for intracellular delivery. Nature 538, 183\u2013192, https:\/\/doi.org\/10.1038\/nature19764 (2016).","journal-title":"Nature"},{"key":"42214_CR42","doi-asserted-by":"publisher","unstructured":"Zhang, J., Shrivastava, S., Cleveland, R. O. & Rabbitts, T. H. Lipid-mRNA nanoparticle designed to enhance intracellular delivery mediated by shock waves. ACS Appl. Mater. Interfaces, https:\/\/doi.org\/10.1021\/acsami.8b21398 (2018).","DOI":"10.1021\/acsami.8b21398"},{"key":"42214_CR43","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 34, 525\u2013527, https:\/\/doi.org\/10.1038\/nbt.3519 (2016).","journal-title":"Nat Biotechnol"},{"key":"42214_CR44","doi-asserted-by":"publisher","first-page":"D710","DOI":"10.1093\/nar\/gkv1157","volume":"44","author":"A Yates","year":"2016","unstructured":"Yates, A. et al. Ensembl 2016. Nucleic Acids Res 44, D710\u2013716, https:\/\/doi.org\/10.1093\/nar\/gkv1157 (2016).","journal-title":"Nucleic Acids Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42214-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42214-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42214-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T08:35:27Z","timestamp":1671266127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-42214-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["42214"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-42214-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"14 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"5760"}}